C
Cerevance
Cerevance a neuroscience company
About Cerevance
Cerevance is a biopharmaceutical startup that operates in the healthcare sector, specifically focusing on neurological disorders. The company is dedicated to developing novel therapies for brain diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's. Its primary clients are patients suffering from these neurological conditions.
Read full description
The company's business model revolves around research, development, and commercialization of innovative drugs. Cerevance uses a proprietary technology platform called Nuclear Enriched Transcript Sort sequencing (NETSseq) to identify novel targets for drug development. This technology helps the company to discover new ways to treat brain diseases.
Cerevance generates revenue through the development and sale of its pharmaceutical products. Additionally, the company also enters into strategic research collaborations with other pharmaceutical companies. For instance, it has a multi-year research collaboration with Merck to discover new targets for Alzheimer's disease.
The company also actively participates in various healthcare conferences and presents its research findings. This not only helps in gaining recognition in the scientific community but also attracts potential investors and partners.
Recently, Cerevance has reported positive results from a Phase 2 clinical trial of CVN424, a new drug for Parkinson's disease. This indicates the company's potential for growth and its commitment to advancing novel therapeutics for brain diseases.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 60.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Latest news
Press, funding announcements and product moves mentioning Cerevance.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | May 2026 | $20M | $255M | GV · Lightstone Ventures · MQB Partners · Dementia Discovery Fund | ↗ |
| SERIES BOther financing | Apr 2024 | $47M | $255M | GV · Gates Frontier · Agent Capital · Lightstone Ventures | ↗ |
Growth signals
Latest recorded traffic for Cerevance is 3.9K monthly website visits, up 44.4% over the last three months. Cerevance's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A17 investors entered at this stage
Lightstone Ventures
Takeda
SV Health Investors
Dementia Discovery Fund
Bill Gates
Takeda Ventures
Foresite Capital
Casdin Capital
Dolby Family Ventures
UPMC Enterprises
GV- GFGates Frontier
Agent Capital
Bioluminescence Ventures
Double Point Ventures
MQB Partners- LVLiferock Ventures
Other known investors1 additional known investor
Rockefeller University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cerevance on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cerevance’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.